Top

Journal of Assisted Reproduction and Genetics

Published in:

01-03-2014 | Gonadal Physiology and Disease

Plasminogen Activator Inhibitor-1 -675 4G/5G Polymorphism and Polycystic Ovary Syndrome Risk: A Meta Analysis

Authors: Ying Liu, Mei-Guo Sun, Rong Jiang, Rui Ding, Zhen Che, Yan-Yan Chen, Ci-Jiang Yao, Xiao-Xia Zhu, Ji-Yu Cao

Published in: Journal of Assisted Reproduction and Genetics | Issue 3/2014

Abstract

Purpose

Several studies have reported that excessive amounts of plasminogen activator inhibitor-1(PAI-1) might increase the incidence of polycystic ovary syndrome(PCOS), but so far the published results were inconsistent. The aim of this study was to further investigate the association between PAI-1 gene polymorphism and the susceptibility to PCOS by performing a meta-analysis.

Methods

A comprehensive literature search for relevant studies was conducted on google scholar, PubMed, the Chinese National Knowledge Infrastructure (CNKI) and the Chinese Biomedical Literature Database (CBM). This meta-analysis was performed using the STATA 11.0 software and the pooled odds ratio (OR) with 95 % confidence interval (CI) was calculated.

Results

Ten case–control studies were included in this meta-analysis with a total of 2,079 cases and 1,556 controls. The results showed that PAI-1 -675 4G/5G polymorphism may increase the risk of PCOS, especially among Asian populations. However, there was no statistically significant association between the polymorphism and PCOS risk in Caucasians.

Conclusion

Our meta-analysis suggests that PAI-1 -675 4G/5G polymorphism may contribute to increasing susceptibility to PCOS in Asians. Detection of the PAI-1 gene polymorphism might be a promising biomarker for the susceptibility of PCOS.

Urbanek M, Nampiaparampil G, D’Souza J, Sefton E, Ackerman C, Legro RS, et al. The role of genetic variation in the lamin a/c gene in the etiology of polycystic ovary syndrome. J Clin Endocrinol Metab. 2009;94:2665–9.PubMedCentralPubMedCrossRef

Asuncion M, Calvo RM, San MJL, Sancho J, Avila S, Escobar-Morreale HF. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab. 2000;85:2434–8.PubMed

March WA, Moore VM, Willson KJ, Phillips DI, Norman RJ, Davies MJ. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum Reprod. 2010;25:544–51.PubMedCrossRef

Li R, Zhang Q, Yang D, Li S, Lu S, Wu X, et al. Prevalence of polycystic ovary syndrome in women in China: a large community-based study. Hum Reprod. 2013;28:2562–9.PubMedCrossRef

Motta AB. The role of obesity in the development of polycystic ovary syndrome. Curr Pharm Des. 2012;18:2482–91.PubMedCrossRef

Diamanti-Kandarakis E. Polycystic ovarian syndrome: pathophysiology, molecular aspects and clinical implications. Expert Rev Mol Med. 2008;10:e3.PubMedCrossRef

Diamanti-Kandarakis E, Economou F. Stress in women: metabolic syndrome and polycystic ovary syndrome. Ann N Y Acad Sci. 2006;1083:54–62.PubMedCrossRef

Dokras A. Cardiovascular disease risk factors in polycystic ovary syndrome. Semin Reprod Med. 2008;26:39–44.PubMedCrossRef

Shan Y, Wang A, Sun Y, Jiang W, Pang B, An Z, et al. Coagulation and fibrinolytic indices during the first trimester of pregnancy in women with polycystic ovary syndrome: a preliminary study. Reproductive sciences (Thousand Oaks, Calif). 2013;20:1390–7.CrossRef

10.

Becker RC. Thrombogenesis in atrial fibrillation: contributing mechanisms and natural history. J Thromb Thrombolysis. 2008;26:262–4.PubMedCrossRef

11.

Diamanti-Kandarakis E, Spina G, Kouli C, Migdalis I. Increased endothelin-1 levels in women with polycystic ovary syndrome and the beneficial effect of metformin therapy. J Clin Endocrinol Metab. 2001;86:4666–73.PubMedCrossRef

12.

DerSimonian R, Kacker R. Random-effects model for meta-analysis of clinical trials: an update. Contemp Clin Trials. 2007;28:105–14.PubMedCrossRef

13.

MANTEL N, HAENSZEL W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48.PubMed

14.

Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539–58.PubMedCrossRef

15.

Glueck CJ, Wang P, Fontaine RN, Sieve-Smith L, Tracy T, Moore SK. Plasminogen activator inhibitor activity: an independent risk factor for the high miscarriage rate during pregnancy in women with polycystic ovary syndrome. Metabolism. 1999;48:1589–95.PubMedCrossRef

16.

San MJL, Corton M, Villuendas G, Sancho J, Peral B, Escobar-Morreale HF. Association of the polycystic ovary syndrome with genomic variants related to insulin resistance, type 2 diabetes mellitus, and obesity. J Clin Endocrinol Metab. 2004;89:2640–6.CrossRef

17.

Zhao JL, Chen ZJ, Zhao YR, Zhao LX, Wang LC, Tang R, et al. Correlation between 4G and 5G genetypes distribution of plasminogen activator inhibitor-1 gene polymorphism in its promoter region with polycystic ovarian syndrome. Zhonghua Fu Chan Ke Za Zhi. 2005;40:528–31.PubMed

18.

Walch K, Grimm C, Huber JC, Nagele F, Kolbus A, Hefler LA. A polymorphism of the plasminogen activator inhibitor-1 gene promoter and the polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol. 2005;123:77–81.PubMedCrossRef

19.

Glueck CJ, Sieve L, Zhu B, Wang P. Plasminogen activator inhibitor activity, 4G5G polymorphism of the plasminogen activator inhibitor 1 gene, and first-trimester miscarriage in women with polycystic ovary syndrome. Metabolism. 2006;55:345–52.PubMedCrossRef

20.

Karadeniz M, Erdogan M, Berdeli A, Saygili F, Yilmaz C. 4G/5G polymorphism of PAI-1 gene and Alu-repeat I/D polymorphism of TPA gene in Turkish patients with polycystic ovary syndrome. J Assist Reprod Genet. 2007;24:412–8.PubMedCentralPubMedCrossRef

21.

Zhang Z, YAng J, Tian Y, Liang H. A study on relationship between PAI-1gene polymorphism and PCOS. Chinese Journal of Women and Child Health Research. 2008;19:541–3.

22.

Sun L, Lv H, Wei W, Zhang D, Guan Y. Angiotensin-converting enzyme D/I and plasminogen activator inhibitor-1 4G/5G gene polymorphisms are associated with increased risk of spontaneous abortions in polycystic ovarian syndrome. J Endocrinol Invest. 2010;33:77–82.PubMed

23.

Lin S, Huiya Z, Bo L, Wei W, Yongmei G. The plasminogen activator inhibitor-1 (PAI-1) gene -844 A/G and -675 4G/5G promoter polymorphism significantly influences plasma PAI-1 levels in women with polycystic ovary syndrome. Endocrine. 2009;36:503–9.PubMedCrossRef

24.

Sales M, Soter M, Candido A, Fernandes A, Oliveira F, Ferreira A, et al. Correlation between plasminogen activator inhibitor-1 (PAI-1) promoter 4G/5G polymorphism and metabolic/proinflammatory factors in polycystic ovary syndrome. Gynecol Endocrinol. 2013;29:936–9.PubMedCrossRef

25.

Glueck CJ, Wang P, Fontaine R, Tracy T, Sieve-Smith L. Metformin-induced resumption of normal menses in 39 of 43 (91%) previously amenorrheic women with the polycystic ovary syndrome. Metabolism. 1999;48:511–9.PubMedCrossRef

26.

Diamanti-Kandarakis E, Palioniko G, Alexandraki K, Bergiele A, Koutsouba T, Bartzis M. The prevalence of 4G5G polymorphism of plasminogen activator inhibitor-1 (PAI-1) gene in polycystic ovarian syndrome and its association with plasma PAI-1 levels. Eur J Endocrinol. 2004;150:793–8.PubMedCrossRef

27.

Zhuang Z, Shen Z, Huang Y, Xu W. Polymorphism in plasminogen activator inhibitor-1 (PAI-1) gene and obese polycystic ovarian syndrome. Medical Innovation of China. 2013;10:1–3.

28.

Attia J, Thakkinstian A, D’Este C. Meta-analyses of molecular association studies: methodologic lessons for genetic epidemiology. J Clin Epidemiol. 2003;56:297–303.PubMedCrossRef

29.

Midgette AS, Wong JB, Beshansky JR, Porath A, Fleming C, Pauker SG. Cost-effectiveness of streptokinase for acute myocardial infarction: A combined meta-analysis and decision analysis of the effects of infarct location and of likelihood of infarction. Med Decis Making. 1994;14:108–17.PubMedCrossRef

30.

Diamanti-Kandarakis E, Piperi C. Genetics of polycystic ovary syndrome: searching for the way out of the labyrinth. Hum Reprod Update. 2005;11:631–43.PubMedCrossRef

31.

Abbott DH, Bacha F. Ontogeny of polycystic ovary syndrome and insulin resistance in utero and early childhood. Fertil Steril. 2013;100:2–11.PubMedCrossRef

32.

Dumesic DA, Richards JS. Ontogeny of the ovary in polycystic ovary syndrome. Fertil Steril. 2013;100:23–38.PubMedCrossRef

33.

Atiomo WU, Bates SA, Condon JE, Shaw S, West JH, Prentice AG. The plasminogen activator system in women with polycystic ovary syndrome. Fertil Steril. 1998;69:236–41.PubMedCrossRef

34.

Cui L, Zhao H, Zhang B, Qu Z, Liu J, Liang X, et al. Genotype-phenotype correlations of PCOS susceptibility SNPs identified by GWAS in a large cohort of Han Chinese women. Hum Reprod. 2013;28:538–44.PubMedCrossRef

35.

Morgan JA, Bombell S, McGuire W. Association of plasminogen activator inhibitor-type 1 (-675 4G/5G) polymorphism with pre-eclampsia: systematic review. PLOS ONE. 2013;8:e56907.PubMedCentralPubMedCrossRef

36.

Zhang T, Pang C, Li N, Zhou E, Zhao K. Plasminogen activator inhibitor-1 4G/5G polymorphism and retinopathy risk in type 2 diabetes: a meta-analysis. BMC Med. 2013;11:1.PubMedCentralPubMedCrossRef

37.

Su MT, Lin SH, Chen YC, Kuo PL. Genetic association studies of ACE and PAI-1 genes in women with recurrent pregnancy loss: a systematic review and meta-analysis. Thromb Haemost. 2013;109:8–15.PubMedCrossRef

Title: Plasminogen Activator Inhibitor-1 -675 4G/5G Polymorphism and Polycystic Ovary Syndrome Risk: A Meta Analysis
Authors: Ying Liu
Mei-Guo Sun
Rong Jiang
Rui Ding
Zhen Che
Yan-Yan Chen
Ci-Jiang Yao
Xiao-Xia Zhu
Ji-Yu Cao
Publication date: 01-03-2014
Publisher: Springer US
Published in: Journal of Assisted Reproduction and Genetics / Issue 3/2014
Print ISSN: 1058-0468
Electronic ISSN: 1573-7330
DOI: https://doi.org/10.1007/s10815-013-0171-2

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Plasminogen Activator Inhibitor-1 -675 4G/5G Polymorphism and Polycystic Ovary Syndrome Risk: A Meta Analysis

Abstract

Purpose

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 3/2014

Testosterone and vitamin E administration up-regulated varicocele-reduced Hsp70-2 protein expression and ameliorated biochemical alterations

Pregnancy with oocytes characterized by narrow perivitelline space and heterogeneous zona pellucida: is intracytoplasmic sperm injection necessary?

Altered microRNA and gene expression in the follicular fluid of women with polycystic ovary syndrome

Perceptions among infertile couples of lifestyle behaviors and in vitro fertilization (IVF) success

The effects of vaginal lubricants on sperm function: an in vitro analysis

When looks are deceiving—the challenge facing embryo quality prognosticators